Recent progress in the intranasal PLGA-based drug delivery for neurodegenerative diseases treatment

  • سال انتشار: 1402
  • محل انتشار: مجله علوم پایه پزشکی ایران، دوره: 26، شماره: 10
  • کد COI اختصاصی: JR_IJBMS-26-10_001
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 234
دانلود فایل این مقاله

نویسندگان

Nasim Aghaei Delche

Department of Biology, Payame Noor University, Tehran, Iran

Reyhaneh Kheiri

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of medical sciences, Tehran, Iran

Behnam Ghorbani Nejad

Department of Toxicology and Pharmacology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran

Mojgan Sheikhi

Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Malihe Sadat Razavi

Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

Milad Rahimzadegan

Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Zahra Salmasi

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

چکیده

One of the most challenging problems of the current treatments of neurodegenerative diseases is related to the permeation and access of most therapeutic agents to the central nervous system (CNS), prevented by the blood-brain barrier (BBB). Recently, intranasal (IN) delivery has opened new prospects because it directly delivers drugs for neurological diseases into the brain via the olfactory route. Recently, PLGA-based nanocarriers have attracted a lot of interest for IN delivery of drugs. This review gathered clear and concise statements of the recent progress of the various developed PLGA-based nanocarriers for IN drug delivery in brain diseases including Alzheimer’s, Parkinson’s, brain tumors, ischemia, epilepsy, depression, and schizophrenia. Subsequently, future perspectives and challenges of PLGA-based IN administration are discussed briefly.

کلیدواژه ها

Drug Delivery, Intranasal, Nanoparticle, Neurodegenerative diseases, PLGA

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.